These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Management of multiple sclerosis: current trials and future options. Noseworthy JH Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064 [TBL] [Abstract][Full Text] [Related]
4. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Bates D Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678 [TBL] [Abstract][Full Text] [Related]
5. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
6. MRI as an outcome in multiple sclerosis clinical trials. Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in multiple sclerosis, Part 2. Becker CC; Gidal BE; Fleming JO Am J Health Syst Pharm; 1995 Oct; 52(19):2105-20; quiz 2132-4. PubMed ID: 8535945 [TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262 [TBL] [Abstract][Full Text] [Related]
11. Current evidence and therapeutic strategies for multiple sclerosis. Wingerchuk DM Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in multiple sclerosis, Part 1. Becker CC; Gidal BE; Fleming JO Am J Health Syst Pharm; 1995 Sep; 52(18):1985-2000. PubMed ID: 8528866 [TBL] [Abstract][Full Text] [Related]
13. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials. Sørensen PS Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048 [TBL] [Abstract][Full Text] [Related]
14. [Selected issues of immunomodulating treatment in multiple sclerosis]. Cendrowski W Neurol Neurochir Pol; 2004; 38(4):299-306. PubMed ID: 15383958 [TBL] [Abstract][Full Text] [Related]
15. Guideline for the use of beta-interferons in patients with multiple sclerosis--a South African proposal. Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA) S Afr Med J; 2004 Nov; 94(11):917-21. PubMed ID: 15587456 [TBL] [Abstract][Full Text] [Related]
16. Disability as an outcome in MS clinical trials. Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462 [TBL] [Abstract][Full Text] [Related]
17. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis]. Lebrun C Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):761-7. PubMed ID: 11677396 [TBL] [Abstract][Full Text] [Related]
18. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Bielekova B; Richert N; Howard T; Blevins G; Markovic-Plese S; McCartin J; Frank JA; Würfel J; Ohayon J; Waldmann TA; McFarland HF; Martin R Proc Natl Acad Sci U S A; 2004 Jun; 101(23):8705-8. PubMed ID: 15161974 [TBL] [Abstract][Full Text] [Related]
19. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Sørensen PS J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763 [TBL] [Abstract][Full Text] [Related]
20. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment. Ouallet JC Rev Neurol (Paris); 2020 Jun; 176(6):500-504. PubMed ID: 32278541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]